Parkinson's Disease - Epidemiology Forecast - 2034

Parkinson's Disease - Epidemiology Forecast - 2034

Key Highlights

According to DelveInsight’s estimates, in 2023, there were approximately 2,718 thousand diagnosed prevalent cases of Parkinson’s disease in the 7MM. Of these, the United States accounted for 45% of the cases, while Japan and Germany represented 9% and 18% of the cases, respectively.

In 2023, EU4 and the UK recorded nearly 1,248 thousand diagnosed prevalent cases of Parkinson's disease. These cases are projected to grow significantly at a compound annual growth rate (CAGR) throughout the study period from 2020 to 2034.

DelveInsight’s epidemiology model projects that Parkinson’s disease cases in the US included nearly 695 thousand males and 517 thousand females in 2023. The model anticipates an increase throughout the study period, with male cases outpacing female cases by 2034, reflecting a higher prevalence among men.

In 2023, among EU4 and UK, the highest Parkinson’s disease cases in Stage III, totaling nearly 409 thousand followed by approximately 406 thousand cases in Stage II. The Stage V had the least cases accounting for 53 thousand cases.

According to DelveInsight’s estimates for 2023, in Japan Parkinson's disease cases were distributed across age groups with nearly 2,030 cases in individuals aged 49 years or younger, 35,525 cases in those aged 50-64, 64,960 cases in the 65-74 age group, and 155,293 cases in individuals aged 75 and above, highlighting a higher prevalence with age.

DelveInsight’s “Parkinson’s Disease – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Parkinson’s Disease, historical and forecasted epidemiology of Parkinson’s Disease in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Parkinson’s Disease Understanding

Parkinson’s Disease Overview

According to the Parkinson’s Foundation, Parkinson’s disease is a neurodegenerative disorder that affects predominately dopamine-producing (dopaminergic) neurons in a specific area of the brain called the substantia nigra. Because Parkinson’s disease develops over time, various stages help identify how symptoms have progressed and what should be expected next. Generally, there are five stages of Parkinson’s disease: Stage I, Stage II, Stage III, Stage IV, and Stage V.

According to the National Health Service (NHS), there are many different symptoms associated with Parkinson’s disease. However, the order in which these develop and their severity differ for individuals. It is unlikely that a person with Parkinson's disease would experience all or most of these. The main symptoms referred to by doctors as parkinsonism include tremors, slowness of movement (bradykinesia), and muscle stiffness (rigidity), which are classified as motor symptoms while non-motor symptoms include cognitive changes, autonomic dysfunctioning, mood and sleep disorders, and others.

While the exact cause of Parkinson’s disease is not known, a combination of genetic and environmental factors is believed to contribute to its development. Other risk factors include age, gender, head trauma, and use of certain medications.

Parkinson’s Disease Diagnosis

Diagnosing Parkinson's disease can be challenging, as there is no definitive test for the condition. Instead, the diagnosis is typically based on a combination of medical history, symptoms, physical and neurological examinations, and sometimes additional tests. MRI may be used only to exclude other causes. DaTscan, an imaging test, can assist in confirming the diagnosis by assessing dopamine levels in the brain. Additionally, advancements in neuroimaging studies, including transcranial Doppler ultrasonography, PET, single-photon emission computed tomography (SPECT), morphometric MRI studies, tractography, functional MRI, and perfusion imaging, are being used to differentiate idiopathic Parkinson's disease from other parkinsonian disorders. Radionuclide imaging modalities like PET and SPECT, using a dopamine transporter ligand, have become the best approach to assess dopamine metabolism and deficiency.

Diagnosing Parkinson's disease presents significant challenges due to its gradual onset and symptom overlap with other neurodegenerative disorders. Early symptoms are often subtle and vary widely among individuals, complicating detection. Moreover, there is no definitive biomarker or diagnostic test, relying instead on clinical evaluations and symptom history, which can lead to misdiagnoses and delays in treatment initiation and care planning.

Further details related to diagnosis are provided in the report…

Parkinson’s Disease Epidemiology

For the purpose of designing the patient-based model for Parkinson’s Disease, the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Parkinson’s Disease, Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease, Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease, Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease, Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease, and Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

DelveInsight’s analyst estimate that in 2023, the United States accounted for the highest cases of diagnosed Parkinson’s disease across the 7MM, totaling 1,210 thousand cases. DelveInsight forecasts a rise in this figure by 2034, reflecting the growing burden of the disease. This trend underscores the increasing healthcare challenge posed by Parkinson’s in the US during the forecast period.

In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Parkinson’s disease in Japan were nearly 257 thousand in 2023.

Among the EU4 and the UK, Germany accounted for the highest diagnosed prevalent cases of Parkinson’s disease with nearly 495 thousand cases in 2023 followed by France accounting for approximately 277 thousand cases. On the other hand, Spain accounted for the least with nearly 149 thousand cases.

In 2023, Japan accounted for approximately 135 thousand cases in males and 123 thousand cases in females, based on gender-specific diagnosed prevalent cases of Parkinson’s disease. These cases are expected to increase during the forecast period.

In the US, nearly 19 thousand cases were diagnosed with Parkinson’s disease in the age group =49 years, 215 thousand cases in 50–64 years, 449 thousand cases in 65–74 years, and 527 thousand cases in =75 years in 2023.

Among the stage-specific diagnosed prevalent cases of Parkinson’s disease in Japan, there were approximately 9 thousand cases for Stage I, 40 thousand cases for Stage II, 107 thousand cases for Stage III, 70 thousand cases for Stage IV, and 31 thousand cases for Stage V in 2023.

In Japan, there were approximately 73 thousand cases of psychosis associated with Parkinson’s disease in 2023.

In the assessment done by DelveInsight, the estimated Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in the US were nearly 508 thousand in 2023.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Parkinson’s Foundation, Miami, US; Stanford University, US; Pacific Health Research and Education Institute, Honolulu, HI US; Department of Neurology, St. Josef-Hospital, Ruhr University Bochum, Germany; Santé publique France, French Public Health Agency, Saint-Maurice, France; Santé publique France, French Public Health Agency, Saint-Maurice, France; Universitario Central de Asturias, Spain; Department of Neurology, The Jikei University Katsushika Medical Center, Tokyo, Japan; and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

The report covers a segment of executive summary, descriptive overview of Parkinson’s Disease, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.

The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.

A detailed review of current challenges in establishing the diagnosis.

Parkinson’s Disease Report Insights

Patient Population

Country-wise Epidemiology Distribution

Total Diagnosed Prevalent Cases of Parkinson’s Disease

Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease

Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease

Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease

Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease

Diagnosed Prevalent Cases of MCI due to Parkinson's Disease

Parkinson’s Disease Report Key Strengths

11 years Forecast

The 7MM Coverage

Parkinson's Disease Epidemiology Segmentation

Parkinson’s Disease Report Assessment

Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

What are the disease risk, burdens, and unmet needs of Parkinson’s Disease? What will be the growth opportunities across the 7MM concerning the patient population of Parkinson's Disease?

What is the historical and forecasted Parkinson's Disease patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

Why is the diagnosed prevalent cases of Parkinson's Disease in Japan lower than the US?

Which country has a high patient share for Parkinson's Disease?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the Parkinson's Disease prevalence cases in varying geographies over the coming years.

A detailed overview of Gender and Age Grade-specific diagnosed prevalence of Parkinson's Disease, along with diagnosed prevalence of Parkinson's Disease Based on severity of airflow limitation and diagnosed prevalence of Parkinson's Disease based on symptoms and exacerbation history.

To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Parkinson's Disease Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Parkinson’s Disease cases in 2023?

The highest cases of Parkinson's Disease was found in the Germany among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Parkinson’s Disease cases in 2023?

The highest cases of Parkinson's Disease were found in the US among the 7MM in 2023.